Navigation Links
Biologic Treatment of Rheumatoid Arthritis Is Low in Brazil, According to Kantar Health Research
Date:9/14/2013

New York, NY (PRWEB) September 14, 2013

Despite the impairment caused by their disease, only 13 percent of rheumatoid arthritis patients in Brazil who are eligible for biologic therapy according to clinical guidelines are actually using a biologic, according to new findings from Kantar Health’s National Health and Wellness Survey (NHWS). The research will be presented today at the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 4th Latin America Conference in Buenos Aires.

Recently updated treatment recommendations from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) suggest that rheumatoid arthritis patients who fail to respond to a disease-modifying antirheumatic drug (DMARD) be administered a biologic DMARD. According to NHWS, more than half of moderate-to-severe rheumatoid arthritis patients in Brazil are eligible for biologic DMARD therapy according to these guidelines; however, only 13 percent actually use these therapies.

Biologic DMARDs are injectable treatments that are typically much more expensive than traditional DMARDs. Only 20 percent of rheumatoid arthritis patients in Brazil reported a monthly income of more than R$10,000, suggesting that they would have significantly worse access to an expensive treatment. In addition, nearly 30 percent of these patients said they have a fear of needles, which might also affect use of an injectable therapy.

“The majority of patients with rheumatoid arthritis in Brazil have high levels of disease severity, and these patients report more physical impairment,” said Dave Pomerantz, Senior Vice President, Kantar Health. “However, treatment rates among patients with rheumatoid arthritis were generally modest overall, particularly with respect to the biologic DMARDs. Our research suggests that poor access to these medications and patients’ attitudes may be hindering uptake of biologics, which would delay the progress of the disease.”

Visit Kantar Health’s website to download the full poster, “Unmet Needs and Biologic Use among Patients with Rheumatoid Arthritis in Brazil.”

About the National Health and Wellness Survey (NHWS)
The study’s results were drawn from the 2011 and 2012 Brazil NHWS, a nationally representative, self-administered survey conducted annually. Topics covered include the health status, attitudes, behaviors and outcomes among adults 18 or older.

Kantar Health conducts the NHWS in the U.S., Europe, Asia and Latin America. The survey is the largest self-reported dataset in the healthcare industry.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11108198.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Kalen Biomedical, LLC Signs Distribution Agreement with Beijing LeBo Biological
2. Molecular Imaging, Inc. Announces New Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging
3. BCC Research Publishes a New Report On Global Markets for Surveillance and Monitoring of Explosive, Chemical, Biological, and Nuclear (Ecbn) Hazards.
4. Distinct brain disorders biologically linked
5. Biological and Biochemical Product Manufacturing in China Industry Research Report – Now Available from IBISWorld
6. BiologicsMD, Inc. Announces The Appointment of J. David Owens as Chief Executive Officer
7. Statement from the Sensory Processing Disorder Foundation Endorsing New Breakthrough Study Revealing Biological Basis for Sensory Processing Disorders in Kids
8. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
9. Silk and cellulose biologically effective for use in stem cell cartilage repair
10. Frequently used biologic agents might cause acute liver injury
11. Men Biologically Programmed to Steer Clear of Friends Wives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology: